Advertisement

Topics

Sigma-Tau Pharmaceuticals, Inc. Changes Name to Leadiant Biosciences, Inc. And Reaffirms its Commitment to Rare Disease Communities

19:30 EST 28 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Celebration and Launch of www.Leadiant.com Commemorate Rare Disease Day 2017 Sigma-Tau Pharmaceuticals, Inc., a leader in the development and commercialization of medicines for patients with rare diseases, today annou...

Other Sources for this Article

Leadiant Biosciences, Inc.:
David Sandoval, 301-948-1041
Sr. Director of Legal Affairs & Chief Compliance Officer
or
SmithSolve LLC on behalf of Leadiant Biosciences:
Robert Murphy, 973-442-1555 ext. 116
Robert.murphy@smithsolve.com

NEXT ARTICLE

More From BioPortfolio on "Sigma-Tau Pharmaceuticals, Inc. Changes Name to Leadiant Biosciences, Inc. And Reaffirms its Commitment to Rare Disease Communities"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...